Sialon Pharmaceutical, Menova, Laimei Pharmaceuticals and other companies released important news

Mondo Finance Updated on 2024-03-04

Sialon Pharmaceutical, Menova, Laimei Pharmaceuticals and other companies released important news

Menova: Perindopril tert-butylammonium salt API obtained the European Postal Code Certificate].

Minova announced that the company's perindopril tert-butylamine salt (API) has received the European CEP Certificate (European Pharmacopoeia Applicability Certificate) from the European Agency for the Quality of Medicines (EAQM).

Sailong Pharmaceutical: The subsidiary obtained the registration certificate of pregabalin capsules].

Sialon Pharmaceutical announced that its wholly-owned subsidiary, Hunan Sialon Pharmaceutical Co., Ltd., recently obtained the "Drug Registration Certificate" of Pregabalin Capsule approved by the State Drug Administration, and the main indications of Pregabalin Capsule are ** postherpetic neuralgia and fibromyalgia.

Laimei Pharmaceutical: Notice on Approval of the Registration Application of the Subsidiary Nicorandil Chemical API.

Limei Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Chongqing Limei Longyu Pharmaceutical Co., Ltd., has received the approval and issuance of nicorandil (specification: 400kg bag, 1 bag bottle) "Notice of Approval of Marketing Application for Chemical APIs".

Huadong Medicine: The exclusive marketed product Zewoquinolensi Injection obtained the drug registration certificate].

ltd., Inc., the company's wholly-owned subsidiary, Zevoqui Inc., announced that the company's exclusive cellular immunity** product, Zevoqui Orense Injection (trade name: Saikaize, R&D code: CT053), has been conditionally approved by the National Medical Products Administration (NMPA) for the treatment of patients with multiple myeloma**: Zevoqui Orense, a cellular immunity** product exclusively sold by the company Injection (trade name: Saikaize, R&D**: CT053) has been conditionally approved by the National Medical Products Administration (NMPA) for the treatment of patients with **or refractory multiple myeloma who have progressed after receiving at least 3** (at least one proteasome inhibitor and one immunomodulator).

Related Pages